Orthopediatrics Corp (NASDAQ:KIDS) Receives Average Recommendation of “Buy” from Analysts

Orthopediatrics Corp (NASDAQ:KIDS) has received an average rating of “Buy” from the six research firms that are covering the stock, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and four have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $47.00.

Several research analysts recently commented on the stock. Zacks Investment Research cut shares of Hess Midstream Partners from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. BTIG Research reduced their target price on shares of Verastem to $8.00 and set a “buy” rating for the company in a report on Friday, May 10th. BidaskClub cut shares of Ames National from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, Needham & Company LLC set a $69.00 price target on shares of Genomic Health and gave the company a “buy” rating in a research note on Wednesday, June 19th.

KIDS traded down $0.93 during trading hours on Friday, hitting $34.83. 57,833 shares of the company’s stock were exchanged, compared to its average volume of 106,890. Orthopediatrics has a 1-year low of $25.11 and a 1-year high of $47.82. The firm has a 50-day moving average price of $38.96. The company has a market capitalization of $524.89 million, a PE ratio of -36.28 and a beta of 0.14. The company has a debt-to-equity ratio of 0.26, a quick ratio of 6.01 and a current ratio of 8.60.

Orthopediatrics (NASDAQ:KIDS) last announced its earnings results on Wednesday, May 8th. The company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.04). Orthopediatrics had a negative return on equity of 16.43% and a negative net margin of 16.71%. The business had revenue of $14.66 million for the quarter, compared to analyst estimates of $14.67 million. As a group, sell-side analysts anticipate that Orthopediatrics will post -0.45 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in KIDS. BNP Paribas Arbitrage SA lifted its stake in Orthopediatrics by 83,150.0% in the first quarter. BNP Paribas Arbitrage SA now owns 1,665 shares of the company’s stock valued at $74,000 after acquiring an additional 1,663 shares during the last quarter. Metropolitan Life Insurance Co. NY acquired a new stake in Orthopediatrics in the fourth quarter valued at $93,000. MetLife Investment Advisors LLC acquired a new stake in Orthopediatrics in the fourth quarter valued at $128,000. Perkins Capital Management Inc. acquired a new stake in Orthopediatrics in the first quarter valued at $221,000. Finally, Sigma Planning Corp acquired a new stake in Orthopediatrics in the first quarter valued at $280,000. Hedge funds and other institutional investors own 48.63% of the company’s stock.

Orthopediatrics Company Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.

See Also: How to Invest in Marijuana Stocks

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.